[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abraham Hulst, MD, PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100565160",false,"NCT06638567","Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.","Postoperative Glucose Control with a Basal Bolus Versus Sliding Scale Insulin Regimen and Its Effect on the Incidence of Surgical Site Infections in People with Type 2 Diabetes Mellitus.","GUIDE","Inclusion Criteria:\n\n* Patients aged 18 or older\n* Diagnosed with type 2 diabetes mellitus\n* Undergoing gastointestinal or vascular surgery\n* Admitted to one of the participating surgical wards\n* Expected duration of stay at least one overnight stay\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with type 1 diabetes mellitus\n* Female of child-bearing potential who is pregnant or breastfeeding.\n* Undergoing complete pancreatectomy\n* Undergoing bariatric surgery\n* Patients using a continuous insulin pump at home\n* Patients undergoing a necrotectomy\u002Fwound debridement from a pre-existent wound.","ALL","18 Years",{"count":19,"type":20},1008,"ESTIMATED","INTERVENTIONAL",[23],"NA","A multicentre, matched-pair, cluster randomised controlled superiority trial to investigate the effect of a proactive basal bolus insulin regimen compared to the reactive sliding scale insulin regimen, targeting a glucose level of 3.9-10.0 mmol\u002FL, to reduce the number of surgical site infections within the first 30 days postoperatively in adult patients with diabetes mellitus type 2.",[26,27],"Diabetes Mellitus, Type 2","Surgical Site Infection",[29,30,31,32,33],"Diabetes Mellitus","Basal bolus regimen","Surgical site infections","Sliding scale","Insulin regimen","RECRUITING","2025-01-28",{"date":37,"type":38},"2025-01-30","ACTUAL",{"date":40,"type":38},"2025-01-03",{"date":42,"type":20},"2027-09",{"name":44,"class":45},"Abraham Hulst, MD, PhD","OTHER",""]